GUIDEPOINT INSIGHTS ASCO 2022 COVERAGE

Join us, June 4th-6th, as Guidepoint Insights hosts our first large in-person group meeting in two years at the 2022 ASCO Conference (live event only, no transcript) featuring KOLs who will dive deeper into clinical updates on major disease sites and research areas.

Dates:
Saturday, June 4, 2022 – Monday, June 6, 2022

Venue:
Venue OverDrive, 2337 S Michigan Ave, Chicago, IL

In-Person Group Meetings

Please select the group meetings you would like to participate in by completing the form below and clicking “submit” at the bottom of the page.

 

    Saturday, June 4th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM CT - Richard Kim
    GI | Associate Professor at H. Lee Moffitt Cancer Center & Research Institute Inc.
    10:00 AM CT - Scott Tagawa
    GU Cancers | Professor at Weill Cornell Medical College, New York
    11:00 AM CT - Michael Morse
    GI Cancers | Professor of Medicine at Duke University Health System Inc.
    12:00 PM CT - Tanguy Seiwert
    NSCLC & Head and Neck Cancer | Assistant Professor and Director of Head and Neck Oncology Disease Group at Johns Hopkins University
    12:00 PM CT - David Aggen
    TCR-T | Assistant Attending L1 - genitourinary oncology service at Memorial Sloan Kettering Cancer Center
    1:00 PM CT - Abdul Mundia
    Leukemia | Professor of Medicine at The Mount Sinai Hospital
    1:00 PM CT - Francisco Esteva
    Breast Cancer | Chief, Breast Medical Oncology at The Northwell Health Cancer Institute
    2:00 PM CT - Joshua Sabari
    Lung Cancer | Medical Oncologist at NYU Langone Medical Center LLC
    2:00 PM CT - Matthew Frigault
    CAR-Ts | Assistant Professor at Harvard Medical School
    3:00 PM CT - Salman Punekar
    Lung/Sarcoma | Medical Oncologist at New York University
    Sunday, June 5th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM CT - Joshua Brody
    Lymphoma | Associate Professor in Hematology and Medical Oncology & Director of the Lymphoma Immunotherapy Program at Mount Sinai Medical Center, Inc.
    10:00 AM CT - Eric Jonasch
    GU Cancers | Professor, Department of Genitourinary Medical Oncology for the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center
    11:00 AM CT - Kevin Kalinsky
    Breast Cancer | Director, Glenn Family Breast Center at Emory University
    11:00 AM CT - Ran Reshef
    CAR-Ts and Transplant | Director of Translational Research, Blood and Marrow Transplantation Clinical Lead, CAR-T Cell Program, Associate Professor of Medicine at Columbia University Medical Center
    12:00 PM CT - Konstantin Dragnev
    Thoracic Oncology | Associate Director for Clinical Research at Norris Cotton Cancer Center
    12:00 PM CT - Thomas Leblanc
    AML/Leukemias | Associate Professor at Duke University Health System Inc.
    1:00 PM CT - Michael Birrer
    Ovarian Cancer | Vice Chancellor at The Winthrop P. Rockefeller Cancer Institute At UAMS
    1:00 PM CT - Jason Luke
    IO | Associate Professor at University of Pittsburgh School of Medicine
    2:00 PM CT - Adi Diab
    Melanoma/Immunotherapy | Assistant Professor at The University of Texas MD Anderson Cancer Center
    2:00 PM CT - Paul Bunn
    Lung Cancer | Professor at the Univ. of Colorado at University of Colorado Denver
    3:00 PM CT - Mark Rubinstein
    IO | Associate Professor/Leader of Priority Research at The Ohio State University
    3:00 PM CT - Sandy Srinivas
    GU Cancers | Oncologist at Stanford University
    4:00 PM CT - Michael Overman
    GI Cancers | Associate Professor, Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center
    Monday, June 6th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    9:30 AM CT - Stuart Packer
    Targeted Therapies | Associate Professor at Albert Einstein College of Medicine
    10:30 AM CT - Neeraj Agarwal
    GU Cancers | Professor at Huntsman Cancer Institute University of Utah Health
    11:00 AM CT - Marco Davila
    CAR-Ts | Associate Member at H. Lee Moffitt Cancer Center and Research Institute Hospital Inc.
    12:00 PM CT - Aurelien Marabelle
    Immunotherapy | Visiting Professor at Stanford University School of Medicine
    12:00 PM CT - Jonathan Ledermann
    Ovarian Cancer | Director Cancer Research UK and UCL Cancer Trials Centre at UCL Cancer Institute Research Trust
    1:00 PM CT - Neil Vasan
    Breast Cancer | Assistant Professor at Columbia University
    2:00 PM CT - Ryan Corcoran
    KRAS/CRC | Associate Professor at Harvard Medical School
    3:00 PM CT - Victoria Wang
    Lung | Oncologist/Assistant Professor at The University of California, San Francisco
    4:00 PM CT - Neil Lyengar
    Breast Cancer | Associate Physician at Rockefeller University

     

    Group meetings will not be recorded and transcripts will not be available after the event.

    For more details on our ASCO events, please email Alyssa Vozza at avozza@guidepoint.com.

    Related Teleconferences

    JUNE 7 | 11:00 AM ET
    ASCO 2022: Updates on Relapsed and Refractory Multiple Myeloma and the Clinical Landscape
    Senior Physician and Professor of Internal Medicine, Hematology, and Oncology, University of Heidelberg Hospital
    SIGN UP
    JUNE 6 | 9:00 AM ET
    China Biotech Pre-ASCO: Evaluating I-O and Cutting-Edge Developments From Legend, BeiGene, I-Mab, JW Therapeutics, CARsgen, and More
    President & CSO, Aleta Biotherapeutics, Inc.
    SIGN UP
    JUNE 3 | 9:30 AM ET
    Pre-ASCO 2022: Liquid Biopsy — Minimal Residual Disease Tests and Diagnostics in Breast Cancer
    Associate Professor of Medicine, Oncology & Hematology, University of Nebraska Medical Center
    SIGN UP
    MAY 31
    Pre-ASCO 2022: PMVP — First-in-Human Data in TP53 Y220C Tumors
    Founding Chair Emeritus and Professor, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
    REQUEST
    MAY 31
    Multiple Myeloma: Update Heading Into ASCO and EHA 2022
    Professor of Oncology and Interim Vice Dean of Research, University of Texas at Austin Dell Medical School
    REQUEST
    MAY 31
    Pre-ASCO 2022: Will ADCs, Bispecifics, or TKIs Prevail for Treating HER2+ Solid Tumors? A Discussion With Karl D’Silva, MD
    Clinical Assistant Professor of Medicine, Tufts University
    REQUEST
    MAY 31
    Pre-ASCO 2022: Arvinas’ PROTAC ER Degrader ARV-471 and Oral SERDs in Breast Cancer
    Assistant Professor, The University of Texas MD Anderson Cancer Center
    REQUEST
    MAY 31
    Pre-ASCO 2022: Liquid Biopsy — Minimal Residual Disease Tests and Diagnostics in Lung Cancer
    Medical Director of Thoracic Oncology and Interventional Pulmonology, Legacy Health
    REQUEST
    MAY 31
    Pre-ASCO 2022: SWTX and GSK Blenrep-GSI Combination — Does Safety Make Up for Efficacy?
    Professor of Clinical Medicine, The University of California, San Francisco
    REQUEST
    MAY 19
    Omakase Series: Pre-ASCO 2022 Immunotherapy With Dr. Thomas Marron
    Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai
    REQUEST
    MAY 19
    Omakase Series: Pre-ASCO 2022 Cell Therapy With Dr. Jae Park
    Associated Attending Physician, Memorial Sloan Kettering Cancer Center
    REQUEST
    MAY 19
    Omakase Series: Pre-ASCO 2022 Lung With Dr. Joshua Sabari
    Medical Oncologist, NYU Langone Health
    REQUEST
    MAY 18
    DLBCL Landscape: Thoughts Ahead of EHA and ASCO 2022 With Dr. Nam Dang
    Professor of Medicine and Deputy Chief of the Division of Hematology & Oncology, University of Florida
    REQUEST
    MAY 18
    Pre-ASCO 2022: WEE1 Inhibitors and Folate Receptor Alpha ADC Preview in Ovarian Cancer
    Gynecologic Oncologist, Virtua Health Foundation
    REQUEST
    MAY 16
    Pre-ASCO 2022: Updates for HER2+ GI Cancers With Richard Kim, MD
    Professor, Service Chief of Medical Gastrointestinal Oncology, and Senior Member in the Gastrointestinal Oncology Department, H. Lee Moffitt Cancer Center & Research Institute
    REQUEST
    MAY 16
    Pre-ASCO 2022: Synthetic Lethality and WEE1 Inhibitors in Ovarian Cancer Plus Emerging Therapies
    Director of Experimental Therapeutics & Herbert Irving Associate Professor of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center
    REQUEST
    MAY 13
    Pre-ASCO 2022: Updates on Colorectal and Pancreatic Cancers With David Hong, MD
    Professor, The University of Texas MD Anderson Cancer Center
    REQUEST
    MAY 12
    Pre-ASCO 2022: Emerging ADCs, ETBs, and Oral SERDs in Breast Cancer
    Associate Professor of Medicine, University of Nebraska
    REQUEST
    MAY 10
    Pre-ASCO 2022: Catalysts in Breast Cancer
    Director of the Breast Medical Oncology Program, Inova Health System
    REQUEST
    MAY 9
    Pre-ASCO 2022: Updates for NRG1 Fusion Cancers With Joshua Sabari, MD
    Assistant Professor of Medicine, Medical Oncology, NYU Langone Health
    REQUEST
    MAY 9
    Pre-ASCO 2022: Updates for Colorectal and Pancreatic Cancer With Ryan Corcoran, MD, Ph.D.
    Associate Professor, Harvard Medical School
    REQUEST
    MAY 9
    Pre-ASCO 2022: FRα Antibody-Drug Conjugates, PARP Inhibitors, and IL-2 Immunotherapy in Ovarian Cancer
    Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School
    REQUEST

    KOL Abstract Review

    MAY 26
    Pre-ASCO 2022: ILT3 Abstract Review from MRK –– Thoughts on LILRB Targeting
    Associate Professor, Mayo Clinic Arizona
    REQUEST
    MAY 27
    Pre-ASCO 2022: MacroGenics’ MGC018 in Prostate Cancer Abstract Review
    Director of Genitourinary Oncology, Montefiore Health System, Inc.
    REQUEST
    MAY 27
    Pre-ASCO 2022: GU Cancers Abstract Review — Seagen’s EV-103 Cohort H and Novel PSMA-Targeted Agents
    Professor of Medicine and Urology, Weill Cornell Medical College, New York
    REQUEST
    MAY 27
    Pre-ASCO 2022: Gamma Delta T-Cell Landscape — Abstracts from LVTX and ACET
    Director of Translational Research for Blood & Marrow Transplantation, Clinical Lead for the CAR-T Cell Program, and Associate Professor of Medicine, Columbia University Irving Medical Center
    REQUEST
    MAY 27
    ASCO 2022: Blueprint Medicines Abstract Review
    Oncologist and Assistant Professor, The University of California, San Francisco
    REQUEST
    MAY 27
    Pre-ASCO 2022: Previewing Liver and Biliary Tract Cancer Abstracts With Mark Yarchoan, MD
    Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
    REQUEST
    MAY 27
    ASCO 2022: Affimed NV Abstract Review
    Professor of Medicine, Division of Oncology, University of North Carolina at Chapel Hill
    REQUEST
    MAY 27
    ASCO 2022 Abstract Review: Magrolimab in HR-MDS
    Assistant Professor of Medicine, Yale School of Medicine
    REQUEST
    MAY 27
    Pre-ASCO 2022: BCMA BiTE –– Elranatamab Abstract Review
    Professor of Medicine, Washington University in St. Louis
    REQUEST
    MAY 31
    ASCO 2022: Gilead Sciences – Phase 3 TROPICS-02 Abstract Review
    Associate Professor, Huntsman Cancer Institute
    REQUEST
    MAY 31
    Pre-ASCO 2022: A Preview of Abstracts for ADCs and Targeted Agents for Solid Tumors With Paul Andrew Antony, MD
    Adjunct Professor of Immunology and Immunotherapy, Johns Hopkins University
    REQUEST
    MAY 31
    Pre-ASCO 2022: Liquid Biopsy — Minimal Residual Disease Tests and Diagnostics in Lung Cancer
    Medical Director of Thoracic Oncology and Interventional Pulmonology, Legacy Health
    REQUEST
    MAY 31
    Pre-ASCO 2022: Arvinas’s PROTAC ER Degrader ARV-471 and Oral SERDs in Breast Cancer
    Assistant Professor in the Department of General Medical Oncology, The University of Texas MD Anderson Cancer Center
    REQUEST
    MAY 31
    Pre-ASCO 2022: Will ADCs, Bispecifics, or TKIs Prevail for Treating HER2+ Solid Tumors? A Discussion With Karl D’Silva, MD
    Clinical Assistant Professor of Medicine, Tufts University
    REQUEST
    MAY 31
    Pre-ASCO 2022: A Discussion on Lung Cancer Abstract Highlights, Including SKYSCRAPER-01 Data Analysis
    Consultant Physician and Professor of Thoracic Medical Oncology, University Hospitals of Leicester NHS Trust
    REQUEST
    MAY 31
    Pre-ASCO 2022: PMVP First-in-Human data in TP53 Y220C Tumors
    Professor & Chair, Oncological, Icahn School of Medicine at Mount Sinai
    REQUEST
    MAY 31
    Pre-ASCO 2022: MRTX KRYSTAL-1 Abstract Review and Expectations for CNS Activity LBA
    Oncologist/Assistant Professor, The University of California, San Francisco
    REQUEST
    JUNE 1
    Pre-ASCO 2022: Merus and Elevation Oncology — Previewing NRG1 Fusion Abstracts With Thai Ho MD, Ph.D.
    Associate Professor, Mayo Clinic
    REQUEST
    JUNE 1
    Pre-ASCO 2022: A First Look at Abstracts for Colorectal and Pancreatic Cancer With Robert Fine, MD
    Director of Experimental Therapeutics & Herbert Irving Associate Professor of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center
    REQUEST